Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Imdusiran (AB-729)
Imdusiran · 1 trial · 1 indication
Intrahepatic drug concentration at day 0 (peak) and week 32 (trough)
| Arm | Type | Description |
|---|---|---|
| Imdusiran (AB-729) | EXPERIMENTAL | Participants receive subcutaneous injections of 60mg, one injection every 8 weeks for 4 doses. |
| Name | Type | Description |
|---|---|---|
| Imdusiran (AB-729) | DRUG | 60mg subcutaneously, every 8 weeks, for a total of 4 doses |
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, over 18 years of age on the date of screening 4. In good general health as evidenced by medical hist...
Imdusiran is an investigational RNA therapy being developed for the treatment of chronic hepatitis B, a persistent viral infection of the liver. It is designed as a small interfering RNA, or siRNA, agent and is currently in Phase 2 clinical development. It has not been approved for commercial use.
Imdusiran targets hepatitis B virus RNA. As a small interfering RNA therapy, it is designed to reduce HBV RNA and viral protein production. This mechanism falls within the siRNA class of RNA-based therapeutics, which act by degrading targeted messenger RNA before it can be translated into protein.
Imdusiran is being developed by Arbutus Biopharma Corporation, which trades on the Nasdaq under the ticker ABUS. Arbutus is the sponsor of the clinical program evaluating the drug in chronic hepatitis B, and the asset has received a Fast Track designation from the FDA.
Imdusiran is in Phase 2 clinical development for chronic hepatitis B. It is an investigational agent and has not been approved by the FDA. The program has received Fast Track designation, a status the FDA grants to investigational therapies intended to treat serious conditions with unmet medical need.
Imdusiran is being studied in the Phase 2 trial NCT06154278, titled Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B. The trial is currently recruiting and is expected to enroll 10 participants in the United States. It is an uncontrolled study open to adults 18 years and older.
Yes, Imdusiran and AB-729 refer to the same investigational compound. AB-729 was the earlier code name used for the asset, and Imdusiran is its current name. Both names appear in the scientific literature and in the title of the ongoing Phase 2 study in chronic hepatitis B.